Fairfield, Bush & Co. Amgen Inc Transaction History

Fairfield, Bush & Co.

$170 Billion
Q4 2024

A detailed history of Fairfield, Bush & Co. transactions in Amgen Inc stock. As of the latest transaction made, Fairfield, Bush & Co. holds 3,671 shares of AMGN stock, worth $1.09 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares

3,671

Previous 3,267 12.37%

Holding current value

$1.09 Million

Previous $1.05 Billion 9.11%

% of portfolio

0.56%

Previous 0.63%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$258.78 - $328.31 $104,547 - $132,637	404 Added 12.37%	3,671 $957 Million
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $27,225 - $29,689	-88 Reduced 2.62%	3,267 $1.05 Billion
Q2 2024 Aug 15, 2024	BUY	$262.75 - $319.31 $116,398 - $141,454	443 Added 15.21%	3,355 $1.05 Billion
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $45,439 - $54,850	-169 Reduced 5.49%	2,912 $828 Million
Q4 2023 Feb 13, 2024	BUY	$255.7 - $288.46 $69,806 - $78,749	273 Added 9.72%	3,081 $887 Million
Q3 2023 Nov 15, 2023	SELL	$218.65 - $271.46 $4.68 Million - $5.82 Million	-21,422 Reduced 88.41%	2,808 $755 Million
Q2 2023 Aug 15, 2023	BUY	$214.27 - $253.37 $424,683 - $502,179	1,982 Added 8.91%	24,230 $5.38 Billion
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $4.6 Million - $5.6 Million	20,367 Added 1082.78%	22,248 $5.38 Billion
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $111,995 - $142,303	-489 Reduced 20.63%	1,881 $494 Million
Q3 2022 Nov 07, 2022	SELL	$224.46 - $253.15 $22,446 - $25,315	-100 Reduced 4.05%	2,370 $534,000
Q2 2022 Aug 09, 2022	SELL	$230.71 - $256.74 $128,044 - $142,490	-555 Reduced 18.35%	2,470 $601,000
Q1 2022 May 06, 2022	SELL	$219.27 - $242.57 $87,708 - $97,028	-400 Reduced 11.68%	3,025 $732,000
Q4 2021 Feb 09, 2022	SELL	$198.88 - $227.6 $1.56 Million - $1.78 Million	-7,840 Reduced 69.6%	3,425 $771,000
Q3 2021 Nov 08, 2021	SELL	$212.27 - $248.7 $2.7 Million - $3.16 Million	-12,720 Reduced 53.03%	11,265 $2.4 Million
Q2 2021 Aug 02, 2021	BUY	$233.58 - $259.14 $291,975 - $323,925	1,250 Added 5.5%	23,985 $5.85 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $99,859 - $116,370	-450 Reduced 1.94%	22,735 $5.66 Million
Q4 2020 Feb 12, 2021	SELL	$216.38 - $257.67 $45,439 - $54,110	-210 Reduced 0.9%	23,185 $5.33 Million
Q3 2020 Nov 18, 2020	SELL	$234.65 - $260.95 $206,492 - $229,636	-880 Reduced 3.63%	23,395 $5.95 Million
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $23,935 - $29,371	121 Added 0.5%	24,275 $5.73 Million
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $48,293 - $64,050	265 Added 1.11%	24,154 $4.9 Million
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $94,605 - $121,600	-500 Reduced 2.05%	23,889 $5.76 Million
Q3 2019 Nov 13, 2019	SELL	$174.11 - $208.62 $67,554 - $80,944	-388 Reduced 1.57%	24,389 $4.72 Million
Q2 2019 Aug 13, 2019	BUY	$166.7 - $195.41 $16,670 - $19,541	100 Added 0.41%	24,777 $4.57 Million
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $1.49 Million - $1.68 Million	-8,255 Reduced 25.07%	24,677 $5.65 Million
Q4 2018 Feb 11, 2019	SELL	$178.4 - $208.25 $89,556 - $104,541	-502 Reduced 1.5%	32,932 $6.41 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $92,645 - $104,445	-500 Reduced 1.47%	33,434 $6.93 Million
Q2 2018 Aug 16, 2018	BUY	$166.05 - $186.51 $43,173 - $48,492	260 Added 0.77%	33,934 $6.26 Million
Q1 2018 May 09, 2018	SELL	$169.43 - $198.0 $116,398 - $136,026	-687 Reduced 2.0%	33,674 $5.74 Million
Q4 2017 Feb 22, 2018	BUY	$168.79 - $188.59 $205,079 - $229,136	1,215 Added 3.67%	34,361 $5.98 Million
Q3 2017 Nov 14, 2017	SELL	$167.29 - $191.0 $33,458 - $38,200	-200 Reduced 0.6%	33,146 $6.18 Million
Q2 2017 Aug 15, 2017	BUY	N/A	33,346	33,346 $5.74 Million

Others Institutions Holding AMGN

# of Institutions

3,161

Shares Held

418M

Call Options Held

8.25M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $159B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

News

Stay updated on Fairfield, Bush & Co. with notifications on news.

Account

Fairfield, Bush & Co. Amgen Inc Transaction History